Goldman Sachs Downgrades DaVita (DVA) to Neutral

Article Related Press Releases (1) Related Articles (1) Stock Quotes (1) Comments (0)

Goldman Sachs downgraded DaVita (NYSE: DVA) from Buy to Neutral with a price target of $120 saying the stock is fairly valued and they see more upside elsewhere.

"While our outlook for core dialysis remains solid and we continue to see strong long-term growth potential in physician (HCP) and dialysis integrated care, we expect slower growth with less upward momentum to our/Street view over the next 12-24 months," the analyst comments.

For an analyst ratings summary and ratings history on DaVita click here. For more ratings news on DaVita click here.

Shares of DaVita closed at $119.21 yesterday, with a 52 week range of $77.81-$119.99.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Morgan Stanley Maintains Bullish Stance on Walter Energy (WLT)
• UPDATE: UBS Starts Insmed (INSM) at Buy
• Goldman Sachs Upgrades Enbridge (ENB) to Conviction Buy

Create E-mail Alert Related Categories

Analyst EPS View, Downgrades

Related Entities

Goldman Sachs

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?